Ipsen Drug Patent Portfolio
Ipsen owns 4 orange book drugs protected by 44 US patents Given below is the list of Ipsen's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11583539 | Treating progressive familial intrahepatic cholestasis (PFIC) with IBAT inhibitors | 12 Nov, 2041 | Active |
| US10975046 | Crystal modifications of odevixibat | 20 Jun, 2039 | Active |
| US11365182 | Crystal modifications of odevixibat | 20 Jun, 2039 | Active |
| US11801226 | Pharmaceutical formulation of odevixibat | 20 Jun, 2039 | Active |
| US11802115 | Pharmaceutical formulation of odevixibat | 20 Jun, 2039 | Active |
| US12091394 | Crystal modifications of odevixibat | 20 Jun, 2039 | Active |
| US10864194 | Methods for treating heterotopic ossification | 08 Jun, 2037 | Active |
| US11622959 | Methods for treating heterotopic ossification | 08 Jun, 2037 | Active |
| US11185519 | Methods of treatment of cholestatic diseases | 30 Mar, 2037 | Active |
| US11331292 | Methods of treatment of cholestatic diseases | 30 Mar, 2037 | Active |
| US11850223 | Methods of treatment of cholestatic diseases | 30 Mar, 2037 | Active |
| US11857523 | Methods of treatment of cholestatic diseases | 30 Mar, 2037 | Active |
| US10456360 | Stabilizing camptothecin pharmaceutical compositions | 15 Oct, 2036 | Active |
| US10993914 | Stabilizing camptothecin pharmaceutical compositions | 15 Oct, 2036 | Active |
| US12059497 | Stabilizing camptothecin pharmaceutical compositions | 15 Oct, 2036 | Active |
| US11344552 | Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin | 19 Aug, 2036 | Active |
| US10980795 | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan | 12 Jun, 2033 | Active |
| US11369597 | Methods for treating pancreatic cancer using combination therapies | 12 Jun, 2033 | Active |
| US9339497 | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan | 12 Jun, 2033 | Active |
| US9364473 | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan | 12 Jun, 2033 | Active |
| US9452162 | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan | 12 Jun, 2033 | Active |
| US9492442 | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan | 12 Jun, 2033 | Active |
| US9717724 | Methods for treating pancreatic cancer using combination therapies | 12 Jun, 2033 | Active |
| US10011633 | IBAT inhibitors for the treatment of liver diseases | 08 Nov, 2031 | Active |
| US10093697 | IBAT inhibitors for the treatment of liver diseases | 08 Nov, 2031 | Active |
| US10487111 | IBAT inhibitors for the treatment of liver diseases | 08 Nov, 2031 | Active |
| US10981952 | IBAT inhibitors for the treatment of liver diseases | 08 Nov, 2031 | Active |
| US11732006 | IBAT inhibitors for the treatment of liver diseases | 08 Nov, 2031 | Active |
| US9694018 | IBAT inhibitors for the treatment of liver disease | 08 Nov, 2031 | Active |
| US10292954 | Composition and method for muscle repair and regeneration | 31 Aug, 2031 | Active |
| US12023312 | Composition and method for muscle repair and regeneration | 31 Aug, 2031 | Active |
| US9314439 | Composition and method for muscle repair and regeneration | 31 Aug, 2031 | Active |
| US9789074 | Composition and method for muscle repair and regeneration | 31 Aug, 2031 | Active |
| US8147867 | Liposomes useful for drug delivery | 29 Aug, 2028 | Active |
| US8329213 | Liposomes useful for drug delivery | 06 Jan, 2027 | Active |
| US10722508 | Liposomes useful for drug delivery | 02 May, 2025 | Active |
| US8703181 | Liposomes useful for drug delivery | 02 May, 2025 | Active |
| US8992970 | Liposomes useful for drug delivery | 02 May, 2025 | Active |
| US9724303 | Liposomes useful for drug delivery | 02 May, 2025 | Active |
| US9730891 | Liposomes useful for drug delivery | 02 May, 2025 | Active |
| US9782349 | Liposomes useful for drug delivery | 02 May, 2025 | Active |
| US7632870 | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof | 09 Sep, 2024 | Expired |
| US7943661 | Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof | 09 Sep, 2024 | Expired |
| US7132416 | Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (IBAT) inhibotory activity for the treatment hyperlipidaemia | 05 Sep, 2022 | Expired |
Latest Legal Activities on Ipsen's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Ipsen.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 29 May, 2024 | US8329213 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 29 May, 2024 | US10864194 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 01 May, 2024 | US9492442 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 14 Mar, 2024 | US9452162 |
| Second letter to regulating agency to determine regulatory review period | 14 Mar, 2024 | US10864194 |
| Second letter to regulating agency to determine regulatory review period | 14 Mar, 2024 | US11622959 |
| Second letter to regulating agency to determine regulatory review period | 14 Mar, 2024 | US9314439 |
| Second letter to regulating agency to determine regulatory review period | 14 Mar, 2024 | US10292954 |
| Second letter to regulating agency to determine regulatory review period | 08 Mar, 2024 | US9694018 |
| Letter from FDA or Dept of Agriculture re PTE application | 07 Feb, 2024 | US9694018 |
| Letter from FDA or Dept of Agriculture re PTE application | 06 Feb, 2024 | US9314439 |
| Letter from FDA or Dept of Agriculture re PTE application | 06 Feb, 2024 | US10864194 |
| Letter from FDA or Dept of Agriculture re PTE application | 06 Feb, 2024 | US11622959 |
| Letter from FDA or Dept of Agriculture re PTE application | 06 Feb, 2024 | US10292954 |
| Letter from FDA or Dept of Agriculture re PTE application | 18 Jan, 2024 | US10093697 |
Ipsen Drug Patents' Oppositions Filed in EPO
Ipsen drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Oct 11, 2017, by Teva Pharmaceuticals Inc.. This opposition was filed on patent number EP05745505A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP17169098A | Feb, 2022 | Generics [UK] Limited | Granted and Under Opposition |
| EP17169098A | Feb, 2022 | Teva Pharmaceutical Industries Ltd. | Granted and Under Opposition |
| EP17169098A | Feb, 2022 | Sandoz AG | Granted and Under Opposition |
| EP13731230A | Feb, 2018 | Teva Pharmaceutical Industries Ltd | Revoked |
| EP05745505A | Oct, 2017 | Teva Pharmaceuticals Inc. | Opposition rejected |
Ipsen's Family Patents
Ipsen drugs have patent protection in a total of 51 countries. It's US patent count contributes only to 28.3% of its total global patent coverage. 7 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Ipsen Drug List
Given below is the complete list of Ipsen's drugs and the patents protecting them.
1. Bylvay
Bylvay is protected by 13 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11583539 | Treating progressive familial intrahepatic cholestasis (PFIC) with IBAT inhibitors |
12 Nov, 2041
(16 years from now)
| Active |
| US10975046 | Crystal modifications of odevixibat |
20 Jun, 2039
(14 years from now)
| Active |
| US11365182 | Crystal modifications of odevixibat |
20 Jun, 2039
(14 years from now)
| Active |
| US11801226 | Pharmaceutical formulation of odevixibat |
20 Jun, 2039
(14 years from now)
| Active |
| US11802115 | Pharmaceutical formulation of odevixibat |
20 Jun, 2039
(14 years from now)
| Active |
| US12091394 | Crystal modifications of odevixibat |
20 Jun, 2039
(14 years from now)
| Active |
| US10011633 | IBAT inhibitors for the treatment of liver diseases |
08 Nov, 2031
(6 years from now)
| Active |
| US10093697 | IBAT inhibitors for the treatment of liver diseases |
08 Nov, 2031
(6 years from now)
| Active |
| US10487111 | IBAT inhibitors for the treatment of liver diseases |
08 Nov, 2031
(6 years from now)
| Active |
| US10981952 | IBAT inhibitors for the treatment of liver diseases |
08 Nov, 2031
(6 years from now)
| Active |
| US11732006 | IBAT inhibitors for the treatment of liver diseases |
08 Nov, 2031
(6 years from now)
| Active |
| US9694018 | IBAT inhibitors for the treatment of liver disease |
08 Nov, 2031
(6 years from now)
| Active |
| US7132416 | Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (IBAT) inhibotory activity for the treatment hyperlipidaemia |
05 Sep, 2022
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Bylvay's drug page
2. Iqirvo
Iqirvo is protected by 6 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11185519 | Methods of treatment of cholestatic diseases |
30 Mar, 2037
(12 years from now)
| Active |
| US11331292 | Methods of treatment of cholestatic diseases |
30 Mar, 2037
(12 years from now)
| Active |
| US11850223 | Methods of treatment of cholestatic diseases |
30 Mar, 2037
(12 years from now)
| Active |
| US11857523 | Methods of treatment of cholestatic diseases |
30 Mar, 2037
(12 years from now)
| Active |
| US7632870 | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof |
09 Sep, 2024
(3 months ago)
| Expired |
| US7943661 | Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof |
09 Sep, 2024
(3 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Iqirvo's drug page
3. Onivyde
Onivyde is protected by 19 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10456360 | Stabilizing camptothecin pharmaceutical compositions |
15 Oct, 2036
(11 years from now)
| Active |
| US10993914 | Stabilizing camptothecin pharmaceutical compositions |
15 Oct, 2036
(11 years from now)
| Active |
| US12059497 | Stabilizing camptothecin pharmaceutical compositions |
15 Oct, 2036
(11 years from now)
| Active |
| US11344552 | Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin |
19 Aug, 2036
(11 years from now)
| Active |
| US10980795 | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
12 Jun, 2033
(8 years from now)
| Active |
| US11369597 | Methods for treating pancreatic cancer using combination therapies |
12 Jun, 2033
(8 years from now)
| Active |
| US9339497 | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
12 Jun, 2033
(8 years from now)
| Active |
| US9364473 | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
12 Jun, 2033
(8 years from now)
| Active |
| US9452162 | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
12 Jun, 2033
(8 years from now)
| Active |
| US9492442 | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
12 Jun, 2033
(8 years from now)
| Active |
| US9717724 | Methods for treating pancreatic cancer using combination therapies |
12 Jun, 2033
(8 years from now)
| Active |
| US8147867 | Liposomes useful for drug delivery |
29 Aug, 2028
(3 years from now)
| Active |
| US8329213 | Liposomes useful for drug delivery |
06 Jan, 2027
(2 years from now)
| Active |
| US10722508 | Liposomes useful for drug delivery |
02 May, 2025
(4 months from now)
| Active |
| US8703181 | Liposomes useful for drug delivery |
02 May, 2025
(4 months from now)
| Active |
| US8992970 | Liposomes useful for drug delivery |
02 May, 2025
(4 months from now)
| Active |
| US9724303 | Liposomes useful for drug delivery |
02 May, 2025
(4 months from now)
| Active |
| US9730891 | Liposomes useful for drug delivery |
02 May, 2025
(4 months from now)
| Active |
| US9782349 | Liposomes useful for drug delivery |
02 May, 2025
(4 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Onivyde's drug page
4. Sohonos
Sohonos is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10864194 | Methods for treating heterotopic ossification |
08 Jun, 2037
(12 years from now)
| Active |
| US11622959 | Methods for treating heterotopic ossification |
08 Jun, 2037
(12 years from now)
| Active |
| US10292954 | Composition and method for muscle repair and regeneration |
31 Aug, 2031
(6 years from now)
| Active |
| US12023312 | Composition and method for muscle repair and regeneration |
31 Aug, 2031
(6 years from now)
| Active |
| US9314439 | Composition and method for muscle repair and regeneration |
31 Aug, 2031
(6 years from now)
| Active |
| US9789074 | Composition and method for muscle repair and regeneration |
31 Aug, 2031
(6 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sohonos's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List